August 7, 2024 09:03 AM EDTUpdated 06:19 PM
Pharma
FDA+

In­spec­tion de­lays hold back BeiGene's Tevim­bra progress once again

Max Bayer

Pharma Reporter

BeiGene will need to wait a bit longer for an FDA de­ci­sion on can­cer im­munother­a­py, Tevim­bra, cit­ing a de­lay in sched­ul­ing clin­i­cal site in­spec­tions. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

With few ef­fi­ca­cy de­tails, In­sil­i­co claims a Phase 2a win in lat­est AI read­out

Roivant makes an­oth­er deal, sell­ing Der­ma­vant to Organon for up to $1.2B

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times